Integrated multidisciplinary model positions Hyderabad as a growing referral hub for advanced pediatric care
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Subscribe To Our Newsletter & Stay Updated
